Display Settings:

Format

Send to:

Choose Destination
Curr Opin HIV AIDS. 2009 Jan;4(1):68-73. doi: 10.1097/COH.0b013e328319bcbe.

Prevention of cervical cancer in women with HIV.

Author information

  • Unité de Biologie de la Reproduction, Groupe Hospitalier Pitié-Salpêtrière, France. isabelle.heard@psl.aphp.fr

Abstract

PURPOSE OF REVIEW:

Cervical cancer, caused by the human papillomavirus (HPV), is the only cancer that is almost preventable through regular screening. In high-resource, as in low-resource and middle-resource countries, women hit by the AIDS epidemic have a high prevalence of infection with HPV and related disease, including cervical cancer. The question whether cervical screening, which helped to reduce dramatically cervical cancer rates through the detection of precancerous lesions in the general population, is as efficient in the setting of HIV is still debated.

RECENT FINDINGS:

The risk for cervical cancer remained high and stable during the last decade in HIV-infected women, and incidence did not decrease with improving CD4 cell counts in women receiving antiviral therapy. Optimal methods to improve both the sensitivity and the specificity of cervical cancer screening are currently evaluated. The use of HPV DNA tests in primary screening endorsed in the general population may be less specific in immunocompromised women and might thus not be as efficient on screening. HPV vaccines, recently available, have no therapeutic effect and might thus not be very useful in preventing cervical cancer in a population highly infected with multiple and persistent HPV.

SUMMARY:

Cervical cancer prevention remains an important goal in HIV-infected women and specific guidelines are warranted for this increasing population.

PMID:
19339941
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk